Roche's Xeloda Gains Approval For Adjuvant Colon Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves capecitabine for adjuvant treatment in patients with Dukes' C colon cancer. Roche is positioning Xeloda as an oral alternative to intravenous 5-fluorouracil/leucovorin-based chemotherapy.